RAS Inhibitors

Daraxonrasib Doubles Survival in Treated Metastatic Pancreatic Cancer in Phase 3 Trial

Published in the New England Journal of Medicine after an ASCO presentation, regulators have authorised expanded access for daraxonrasib pending formal review.